var data={"title":"Retapamulin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Retapamulin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/324249?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=retapamulin-drug-information\" class=\"drug drug_general\">see &quot;Retapamulin: Drug information&quot;</a> and <a href=\"topic.htm?path=retapamulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Retapamulin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599865\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Altabax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708440\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Pleuromutilin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Topical</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708445\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=retapamulin-drug-information\" class=\"drug drug_general\">see &quot;Retapamulin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Impetigo: Note:</b> Total treatment area should not exceed 2% of total body surface area or 100 cm<sup>2</sup> total body surface area, whichever is less. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 to &lt;9 months: Limited data available: Topical: Apply to lesions twice daily for 5 days (Stevens, 2014); <b>Note:</b> In trials, infants 2 to 9 months of age had higher systemic exposure than older pediatric patients, monitor closely for systemic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;9 months, Children, and Adolescents: Topical: Apply to affected area (lesions) twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Impetigo:</b> Topical: Apply to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm<sup>2</sup> total body surface area.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599958\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Altabax: 1% (15 g, 30 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599866\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708446\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: May cover treatment area with sterile bandage or gauze dressing if needed to prevent accidental transfer of ointment into eyes, mouth, or other areas. Concomitant use with other topical products to the same treatment area has not been evaluated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599945\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&#730;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708441\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of impetigo caused by susceptible strains of <i>S. pyrogenes</i> or methicillin-susceptible <i>S. aureus</i> (FDA approved in ages &ge;9 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599939\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Eczema (infants, children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site irritation (adults), application site pruritus (infants, children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, application site burning, application site pain, contact dermatitis, epistaxis, erythema, hypersensitivity reaction, increased creatine phosphokinase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599933\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599934\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin irritation: If sensitization or severe local skin irritation occurs, wipe ointment off and discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For external use only; not for intranasal, intravaginal, ophthalmic, oral, or mucosal application. Concomitant use with other topical products to the same treatment area has not been evaluated.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299993\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222744\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=96962&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Retapamulin. Management: Avoid this combination in patients less than 2 years old.  No action is required in other populations.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599870\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599871\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599946\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Primarily bacteriostatic; inhibits normal bacterial protein biosynthesis by binding at a unique site (protein L3) on the ribosomal 50S subunit; prevents formation of active 50S ribosomal subunits by inhibiting peptidyl transfer and blocking P-site interactions at this site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4599948\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Topical: Low; increased when applied to abraded skin; age dependent; absorption highest in younger patients </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 2 to 24 months: Overall, in trials, 46% of subjects 2 to 24 months of age had measurable serum concentration compared to 7% of those &ge;2 years. Within the 2 to 24 month age group, the aggregate of infants 2 to 9 months had a higher proportion of patients with measurable serum concentration than those aged 9 to 24 months (69% vs 32%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge; 2 years, Adolescents, and Adults: Low; increased when applied to abraded skin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP 3A4; extensively metabolized by mono-oxygenation and di-oxygenation to multiple metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5736763\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Altabax External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (15 g): $328.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038893\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Altargo (AR, AT, AU, BE, BR, CL, CO, CR, CY, CZ, DE, DK, DO, EE, ES, GB, GR, GT, HN, HR, IN, IS, IT, KR, KW, LK, LT, MT, MX, NI, NL, NO, PA, PE, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TR);</li>\n      <li>Altarho (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Altabax (retapamulin) [prescribing information]. Research Triangle Park, NC: Glaxo SmithKline; August 2013. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parish LC, Jorizzo JL, Breton JJ, et al, &ldquo;Topical Retapamulin Ointment (1%, wt/wt) Twice Daily for 5 Days Versus Oral Cephalexin Twice Daily for 10 Days in the Treatment of Secondarily Infected Dermatitis: Results of a Randomized Controlled Trial,&rdquo; <i>J Am Acad Dermatol</i>, 2006, 55(6):1003-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/retapamulin-pediatric-drug-information/abstract-text/17097398/pubmed\" target=\"_blank\" id=\"17097398\">17097398</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/retapamulin-pediatric-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 96962 Version 31.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F4599865\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F25708440\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F25708445\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F4599958\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F4599866\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25708446\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F4599945\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25708441\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4599939\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4599933\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4599934\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299993\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222744\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F4599870\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4599871\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4599946\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F4599948\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5736763\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038893\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/96962|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=retapamulin-drug-information\" class=\"drug drug_general\">Retapamulin: Drug information</a></li><li><a href=\"topic.htm?path=retapamulin-patient-drug-information\" class=\"drug drug_patient\">Retapamulin: Patient drug information</a></li></ul></div></div>","javascript":null}